文献速递特殊人群用药治疗药物监测与药物基因组学

妊娠期长效卡博特韦/利匹韦林超说明书高剂量给药:治疗药物监测病例研究

Off-label dosing of long-acting injectable cabotegravir and rilpivirine during pregnancy: A case study with therapeutic drug monitoring.
PubMed 文献 · Br J Clin Pharmacol · 2025-12-16

报告一名围产期感染HIV、多种合并症及III级肥胖的年轻女性,在孕前及整个妊娠期接受每月高剂量长效肌注卡博特韦/利匹韦林(CAB/RPV=600 mg/900 mg)联合皮下来那卡帕韦的超说明书个体化治疗,并全程进行治疗药物监测。妊娠7至32周期间CAB和RPV谷浓度分别下降50%和27%,但仍高于蛋白调整IC90,病毒载量维持<20 copies/mL,未出现母体、妊娠或婴儿不良安全结局。

要点

  • 妊娠期每月高剂量CAB/RPV虽血药浓度下降,但仍高于治疗阈值且病毒学抑制维持。
  • 高剂量CAB/RPV暴露未导致母体、妊娠或婴儿不良安全结局。
  • 产后7周单次高剂量注射后CAB/RPV谷浓度较孕7周分别高56%和73%。

核心结论

  • 妊娠期使用每月高剂量CAB/RPV(600 mg/900 mg)联合来那卡帕韦并配合治疗药物监测,可维持病毒学抑制且未观察到不良安全结局。

研究设计与样本

  • 单例病例研究,对象为围产期感染HIV、多种合并症及III级肥胖的年轻女性,孕前及整个妊娠期接受每月高剂量肌注CAB/RPV(600 mg/900 mg)联合皮下来那卡帕韦,并全程进行CAB和RPV治疗药物监测。

主要发现

  • 妊娠7周时血浆CAB和RPV谷浓度分别为2.58 mg/L和0.11 mg/L,是各自蛋白调整IC90的16倍和9倍。
  • 妊娠7至32周期间血浆CAB和RPV谷浓度分别降至1.28 mg/L和0.08 mg/L,但仍高于两者蛋白调整IC90。
  • 产后7周接受一次每月高剂量CAB/RPV注射后,血浆CAB和RPV谷浓度分别为4.02 mg/L和0.19 mg/L,较孕7周分别高56%和73%。
  • 妊娠早至晚孕期卡博特韦和利匹韦林浓度分别下降50%和27%,但血浆暴露仍高于治疗阈值,病毒载量维持<20 copies/mL。
  • 较高CAB和RPV暴露未导致母体、妊娠或婴儿不良安全结局;产后7周CAB/RPV转换为标准双月给药,产后33周仍维持检测不到病毒。

临床怎么用

  • 对于复杂(如III级肥胖)HIV感染孕妇,可考虑在治疗药物监测下个体化使用每月高剂量CAB/RPV以维持病毒学抑制。
  • 妊娠期应监测CAB和RPV谷浓度以确保高于蛋白调整IC90,产后需注意浓度升高并适时转换回标准双月给药。

局限性

  • 仅为单例病例报告,结果不能推广至所有妊娠期HIV感染者。
  • 后续妊娠可能需要调整长效CAB/RPV剂量,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report individualized off-label monthly use of a high dose of long-acting intramuscular cabotegravir/rilpivirine (CAB/RPV = 600 mg/900 mg) co-administered preconceptionally and throughout pregnancy with subcutaneous lenacapavir to a young woman with perinatally acquired HIV, multiple comorbidities, and class III obesity. Therapeutic drug monitoring for CAB and RPV was performed throughout the pregnancy and postpartum. At 7 weeks gestation, the plasma CAB and RPV Ctroughs were 16 (2.58 mg/L) and 9 (0.11 mg/L) times above the respective protein adjusted (PA)-IC90. From 7 to 32 weeks of gestation, plasma CAB and RPV Ctroughs decreased to 1.28 and to 0.08 mg/L, respectively, but remained above PA-IC90 for both drugs. After receiving one monthly high-dose CAB/RPV injection after delivery at 7 weeks postpartum, the plasma CAB and RPV Ctroughs were 4.02 and 0.19 mg/L, 56% and 73% higher than at 7 weeks of gestation. Despite a decrease in cabotegravir (50%) and rilpivirine (27%) concentrations between first and third trimesters, plasma exposures remained above therapeutic thresholds and viral load <20 copies/mL was maintained throughout pregnancy. Higher CAB and RPV exposures did not result in adverse maternal, pregnancy or infant safety outcomes. At 7 weeks postpartum, CAB/RPV was switched to standard bimonthly dosing. At 33 weeks postpartum, the patient remained undetectable on standard CAB/RPV bimonthly dose, although subsequent pregnancies might require long-acting CAB/RPV dosing adjustments. Our case of empiric use of high-dose CAB/RPV with monthly injections and therapeutic drug monitoring during pregnancy in a complex patient with class III obesity provides novel insights into pharmacokinetics of long-acting CAB/RPV.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Rakhmanina N, Unternaher J, Williams T, et al. Off-label dosing of long-acting injectable cabotegravir and rilpivirine during pregnancy: A case study with therapeutic drug monitoring. Br J Clin Pharmacol. 2025. PMID: 41401967. doi:10.1002/bcp.70424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。